Literature DB >> 12217343

Purity of spiking agent affects partitioning of prions in plasma protein purification.

M Vey1, H Baron, T Weimer, A Gröner.   

Abstract

Prions are not detectable in the blood or plasma of persons afflicted with classical or variant Creutzfeldt-Jakob disease, and they have never been shown to be transmitted by blood or plasma products. Despite the uncertainty as to the presence and biophysical properties of prions in plasma, prion removal studies have been conducted using brain homogenate or microsomes prepared from prion-infected rodent brains as model prions. In this study, we compare the partitioning of different prion spiking agents, having different biophysical properties, in the processes used for plasma protein purification. We have found that membrane-bound prion spiking agents partition similarly, whereas purified, unbound pathogenic prion proteins can have significantly different partitioning properties depending on the conditions in the production process. We conclude that prion spiking studies for the evaluation of prion reduction in plasma protein purification should employ spiking agents with different biophysical properties to mimic partitioning of the theoretical prion contaminant. This will give greater assurance as to the prion safety margins of the life-saving plasma protein therapeutics and excipients. Copyright 2002 The International Association for Biologicals. Published by Elsevier Science Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12217343     DOI: 10.1006/biol.2002.0327

Source DB:  PubMed          Journal:  Biologicals        ISSN: 1045-1056            Impact factor:   1.856


  5 in total

1.  A Heparin Purification Process Removes Spiked Transmissible Spongiform Encephalopathy Agent.

Authors:  Cyrus Bett; Ksenija Grgac; Dianna Long; Michael Karfunkle; David A Keire; David M Asher; Luisa Gregori
Journal:  AAPS J       Date:  2017-01-23       Impact factor: 4.009

2.  Removal of transmissible spongiform encephalopathy prion from large volumes of cell culture media supplemented with fetal bovine serum by using hollow fiber anion-exchange membrane chromatography.

Authors:  Ming Li Chou; Andy Bailey; Tiffany Avory; Junji Tanimoto; Thierry Burnouf
Journal:  PLoS One       Date:  2015-04-13       Impact factor: 3.240

Review 3.  Ensuring the biologic safety of plasma-derived therapeutic proteins: detection, inactivation, and removal of pathogens.

Authors:  Kang Cai; Todd M Gierman; JoAnn Hotta; Christopher J Stenland; Douglas C Lee; Dominique Y Pifat; Steve R Petteway
Journal:  BioDrugs       Date:  2005       Impact factor: 5.807

Review 4.  Pathogen inactivation and removal methods for plasma-derived clotting factor concentrates.

Authors:  Robert Klamroth; Albrecht Gröner; Toby L Simon
Journal:  Transfusion       Date:  2013-09-30       Impact factor: 3.157

Review 5.  Pathogen safety of plasma-derived products - Haemate P/Humate-P.

Authors:  A Gröner
Journal:  Haemophilia       Date:  2008-11       Impact factor: 4.287

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.